Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 10/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 6/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17859230 | 0.86 | ALDH1A1 (0.42) | MAPTSMN1; SMN2MEN1KMT2AHTT | |
| SCHEMBL17859492 | 0.83 | CYP1A2 (0.43) | NPC1MAPTGAARAB9ASMN1; SMN2 | |
| SCHEMBL19742255 | 0.80 | MAPT (0.41) | NPC1MAPTGAARAB9ASMN1; SMN2 | |
| SCHEMBL20746466 | 0.78 | ACP1 (0.52) | NPC1MAPTGAARAB9ASMN1; SMN2 | |
| SCHEMBL3591269 | 0.77 | MAPT (0.60) | NPC1MAPTGAARAB9ASMN1; SMN2 | |
| SCHEMBL2380048 | 0.76 | SMN1; SMN2 (0.59) | MAPTRAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL30723284 | 0.74 | CYP3A4 (0.58) | MAPTGAASMN1; SMN2MEN1KMT2A | |
| SCHEMBL15253836 | 0.74 | CYP3A4 (0.58) | MAPTGAASMN1; SMN2MEN1KMT2A | |
| SCHEMBL7587421 | 0.73 | NPC1 (0.51) | NPC1MAPTGAASMN1; SMN2HTT | |
| SCHEMBL19742292 | 0.73 | NPC1 (0.43) | NPC1MAPTGAARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170369470-A1 | Cyclic Compounds and Uses Thereof | Karyopharm Therapeutics Inc. | 2017-12-28 | — | — | US | disclosed |
| US-20170369470-A1 | Cyclic Compounds and Uses Thereof | Karyopharm Therapeutics Inc. | 2017-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369470-A1 | Cyclic Compounds and Uses Thereof | MALT1, BCL9, BCL6 | NPC1 1213/4885MAPT 115/4885GAA 3214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.